Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy

Paddubny, Kiryl; Freitag, Martin T.; Kratochwil, Clemens; Koerber, Stefan A.; Radtke, Jan Philipp; Сакович, Р А; Kopka, Klaus; Giesel, Frederik L.

doi:10.1016/j.clgc.2017.09.014

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In light of the growing availability of 68 Ga-or 18 F-labeled PSMA-targeted imaging agents (19)(20)(21)(22), the number of molecular imaging specialists that routinely interpret PET scans with these compounds outside controlled clinical trials is expanding (23). However, numerous studies have reported pitfalls in the reading of PSMA-targeted PET studies, including studies of Paget disease, sarcoidosis, or nervous tissue such as ganglia (7-10).…”

Section: Discussionmentioning

confidence: 99%

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging

Werner

Bundschuh²,

Bundschuh³

et al. 2018

J Nucl Med

View full text Add to dashboard Cite

Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)-targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of F-DCFPyL (2-(3-{1-carboxy-5-[(6-F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Four readers (2 experienced readers (ERs,>3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs, <1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 50 F-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion-based, on an organ-based, and on an overall PSMA-RADS score-based level were computed. The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, ≥0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) ( = 0.005). PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging

Werner

Bundschuh²,

Bundschuh³

et al. 2018

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Paddubny et al presented its use in the setting of BCR and equivocal findings on MRI ( Figure 9 ). In this study, the 18 F-PSMA-1007 PET/CT scan allowed identification of local PCa recurrence, which was otherwise not seen on mpMRI ( 62 ).…”

Section: Psma-pet Tracersmentioning

confidence: 92%

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Czarniecki

Mena

Lindenberg

et al. 2018

Transl. Androl. Urol

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) is an emerging prostate cancer imaging method, which has been reported to have a higher sensitivity and specificity than the currently approved PET imaging agents. Multiple PSMA ligands are being investigated around the world and applications range from primary tumor characterization, to local staging, biochemical recurrence, metastasis, and image-guided interventions. The most investigated PET tracers are labelled with 68-Gallium or 18-Fluoride and are discussed in this review. Additionally, 99mTc labeled PSMA agents for single photon emission computed tomography (SPECT) imaging are elucidated as an alternative method of PSMA image acquisition.

show abstract

Molecular Imaging of Prostate Cancer

Nikpanah

Mena

Choyke

et al. 2020

Prostate MRI Essentials

View full text Add to dashboard Cite

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy

Cited by 4 publications

References 24 publications

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Molecular Imaging of Prostate Cancer

Contact Info

Product

Resources

About

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy

Cited by 4 publications

References 24 publications

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Molecular Imaging of Prostate Cancer

Contact Info

Product

Resources

About

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging